M. E. Scheurer, G. Tortolero-luna, and K. Adler-storthz, Human papillomavirus infection: biology, epidemiology, and prevention, Int J Gynecol Cancer, vol.15, issue.5, pp.727-773, 2005.

D. M. Parkin and F. Bray, Chapter 2: The burden of HPV-related cancers, Vaccine, vol.24, 2006.

M. Bouassa, R. S. , M. Simaleko, M. Camengo, S. P. Mossoro-kpinde et al., Unusual and unique distribution of anal high-risk human papillomavirus (HR-HPV) among men who have sex with men living in the Central African Republic, PLoS One, vol.13, issue.5, p.197845, 2018.

V. Bouvard, R. Baan, K. Straif, Y. Grosse, B. Secretan et al., A review of human carcinogens-Part B: biological agents, Lancet Oncol, vol.10, issue.4, pp.70096-70104, 2009.

S. De-sanjose, W. G. Quint, L. Alemany, D. T. Geraets, J. E. Klaustermeier et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study, Lancet Oncol, vol.11, issue.11, pp.70230-70238, 2010.

E. M. De-villiers, C. Fauquet, T. R. Broker, H. U. Bernard, and . Zur-hausen, Classification of papillomaviruses. Virology, vol.324, pp.17-27, 2004.

H. De-vuyst, L. Alemany, C. Lacey, C. J. Chibwesha, V. Sahasrabuddhe et al., The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine, vol.31, pp.32-46, 2013.

J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, issue.5, pp.359-86, 2015.

, Projections of mortality and causes of death, 2015.

M. Bouassa, R. S. Prazuck, T. Lethu, T. Jenabian, M. A. Meye et al., Bé lec L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease, Expert Rev Anti Infect Ther, vol.15, issue.6, pp.613-627, 2017.

D. M. Harper and L. R. Demars, HPV vaccines-A review of the first decade, Gynecol Oncol, vol.146, issue.1, pp.196-204, 2017.

L. A. Pinto, J. Dillner, S. Beddows, and E. R. Unger, Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine, vol.36, pp.4792-4799, 2018.

R. Luckett and S. Feldman, Impact of 2-, 4-and 9-valent HPV vaccines on morbidity and mortality from cervical cancer, Hum Vaccin Immunother, vol.12, issue.6, pp.1332-1374, 2016.

Á. Ruiz-sternberg, E. D. Moreira, J. A. Restrepo, E. Lazcano-ponce, R. Cabello et al., Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women, Papillomavirus Res, vol.5, pp.63-74, 2018.

W. Chen, Y. Zhao, X. Xie, J. Liu, J. Li et al., Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up. Vaccine, vol.37, pp.889-897, 2019.

S. De-sanjosé, B. Serrano, S. Tous, M. Alejo, B. Lloveras et al., Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr, vol.2, p.45, 2019.

E. J. Mavundza, A. B. Wiyeh, P. W. Mahasha, G. Halle-ekane, and C. S. Wiysonge, A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus, Hum Vaccin Immunother, 2019.

Z. Q. Toh, J. Kosasih, F. M. Russell, S. M. Garland, E. K. Mulholland et al., Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infect Drug Resist, vol.12, pp.1951-1967, 2019.

, Vaccins contre les papillomavirus humains: note de synthèse de l'OMS, vol.92, pp.241-268, 2017.

F. X. Bosch, C. Robles, M. Díaz, M. Arbyn, I. Baussano et al., HPV-FASTER: broadening the scope for prevention of HPV-related cancer, Nat Rev Clin Oncol, vol.13, issue.2, pp.119-151, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02451776

F. X. Bosch, C. Robles, and . Hpv-faster, Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns, Salud Publica Mex, vol.60, issue.6, pp.612-616, 2018.

P. L. Stern and R. B. Roden, Opportunities to improve immune-based prevention of HPV-associated cancers, Papillomavirus Res, vol.7, pp.150-153, 2019.

L. Bruni, M. Diaz, X. Castellsagué, E. Ferrer, F. X. Bosch et al., Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings, J Infect Dis, vol.202, issue.12, pp.1789-99, 2010.

J. C. Mccloskey, W. M. Kast, J. P. Flexman, D. Mccallum, M. A. French et al., Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions, Papillomavirus Res, vol.4, pp.90-98, 2017.

M. Chironna, A. Neve, A. Sallustio, A. De-robertis, M. Quarto et al., Frequency of human papillomavirus infection and genotype distribution among women with known cytological diagnosis in a Southern Italian region, J Prev Med Hyg, vol.51, issue.4, pp.139-184, 2010.

M. L. Tornesello, R. Cassese, D. Rosa, N. Buonaguro, L. Masucci et al., High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy, APMIS, vol.119, issue.10, p.21917007, 2011.

M. F. Van-der-wal, A. C. Diepenmaat, J. M. Pel, and R. A. Hirasing, Vaccination rates in a multicultural population, Arch Dis Child, vol.90, issue.1, pp.36-40, 2005.

D. M. Bruno, T. E. Wilson, F. Gany, and A. Aragones, Identifying human papillomavirus vaccination practices among primary care providers of minority, low-income and immigrant patient populations. Vaccine, vol.32, pp.4149-54, 2014.

M. Grandahl, M. Larsson, T. Dalianis, C. Stenhammar, . Tydé-n-t et al., Catch-up HPV vaccination status of adolescents in relation to socioeconomic factors, individual beliefs and sexual behaviour, PLoS One, vol.12, issue.11, p.187193, 2017.

S. P. Møller, M. Kristiansen, and M. Norredam, Human papillomavirus immunization uptake among girls with a refugee background compared with Danish-born girls: a national register-based cohort study, Eur J Cancer Prev, vol.27, issue.1, pp.42-47, 2018.

F. Grillo, J. Vallée, and P. Chauvin, Inequalities in cervical cancer screening for women with or without a regular consulting in primary care for gynaecological health, Prev Med, vol.54, issue.3-4, pp.259-65, 2012.

F. Grillo, M. Soler, and P. Chauvin, L'absence de dépistage du cancer du col de l'utérus en fonction des caracté ristiques migratoires chez les femmes de l'agglomération parisienne en 2010, Bull Epidemiol Hebd, vol.2, pp.45-47, 2012.

H. Autorité-de-santé, Dépistage et prévention du cancer du col de l'uté rus: actualisation du référentiel de pratiques de l'examen périodique de santé (EPS), HAS, 2019.

, Haute Autorité de Santé . Dépistage É valuation de la recherche des papillomavirus humains (HPV) en dé pistage primaire des lé sions précancéreuses et cancé reuses du col de l'uté rus et de la place du double immunomarquage p16/Ki67. Synthèse et recommandations. P. 36, 2019.

R. Roden and P. L. Stern, Opportunities and challenges for human papillomavirus vaccination in cancer, Nat Rev Cancer, vol.18, issue.4, pp.240-254, 2018.

Z. Wang, B. G. Hansson, O. Forslund, L. Dillner, M. Sapp et al., Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA, J Clin Microbiol, vol.34, issue.12, pp.3056-62, 1996.

T. Sasagawa, R. C. Rose, K. K. Azar, A. Sakai, and M. Inoue, Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids, Int J Cancer, vol.104, issue.3, pp.328-363, 2003.

Z. Z. Mbulawa, A. L. Williamson, D. Stewart, J. A. Passmore, L. Denny et al., Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease, J Gen Virol, vol.89, p.18343831, 2008.

D. J. Marais, J. M. Best, R. C. Rose, P. Keating, R. Soeters et al., Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia, J Med Virol, vol.65, issue.1, pp.149-54, 2001.

L. Gissmann, Immunologic responses to human papillomavirus infection, Obstet Gynecol Clin North Am, vol.23, issue.3, pp.625-664, 1996.

J. J. Carter and D. A. Galloway, Humoral immune response to human papillomavirus infection, Clin. Dermatol, vol.15, pp.249-259, 1997.

J. J. Carter, L. A. Koutsky, J. P. Hughes, S. K. Lee, J. Kuypers et al., Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection, J Infect Dis, vol.181, issue.6, pp.1911-1920, 2000.

A. Touzé, S. De-sanjosé, P. Coursaget, M. R. Almirall, V. Palacio et al., Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes, J Clin Microbiol, vol.39, issue.12, pp.4344-4352, 2001.

M. Stanley, HPV-immune response to infection and vaccination. Infect Agent Cancer, vol.5, p.19, 2010.

M. Scherpenisse, R. M. Schepp, M. Mollers, C. J. Meijer, G. A. Berbers et al., Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses, PLoS One, vol.8, issue.9, 2013.

M. E. Hagensee, L. A. Koutsky, S. K. Lee, T. Grubert, J. Kuypers et al., Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions, J Infect Dis, vol.181, issue.4, pp.1234-1243, 2000.

L. Bé-lec, T. Dupré, T. Prazuck, C. Tévi-bé-nissan, J. M. Kanga et al., Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection, J Infect Dis, vol.172, issue.3, pp.691-698, 1995.

T. Sasagawa, H. Yamazaki, Y. Z. Dong, S. Satake, and M. Tateno, Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions, Int J Cancer, vol.75, issue.4, pp.529-564, 1998.

A. Petter, K. Heim, M. Guger, C. Nig, A. Christensen et al., Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women, J Gen Virol, vol.81, pp.701-709, 2000.

J. Dillner, The serological response to papillomaviruses, Semin. Cancer Biol, vol.9, pp.423-430, 1999.

H. J. Bontkes, T. D. De-gruijl, J. M. Walboomers, J. T. Schiller, J. Dillner et al., Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16, J Gen Virol, vol.80, pp.409-426, 1999.

, Population étrangère par sexe et â ge en 2012, 2015.

L. Bé-lec, D. Meillet, M. Lévy, A. Georges, C. Té-vi-bénissan et al., Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays, Clin Diagn Lab Immunol, vol.2, issue.1, pp.57-61, 1995.

D. Solomon, D. Davey, R. Kurman, A. Moriarty, D. O'connor et al., Bethesda System: terminology for reporting results of cervical cytology, JAMA, vol.287, issue.16, pp.2114-2123, 2001.

M. Bouassa, R. S. Nodjikouambaye, Z. A. Sadjoli, D. Adawaye, C. Pé-ré et al., High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N'Djamena, Chad. PLoS One, vol.14, p.217486, 2019.

C. B. Buck and C. D. Thompson, Production of papillomavirus-based gene transfer vectors, Curr Protoc Cell Biol, 2007.

C. B. Buck, C. D. Thompson, J. N. Roberts, M. Müller, D. R. Lowy et al., Carrageenan is a potent inhibitor of papillomavirus infection, PLoS Pathog, vol.2, issue.7, p.69, 2006.

J. N. Roberts, C. B. Buck, C. D. Thompson, R. Kines, M. Bernardo et al., Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan, Nat Med, vol.13, issue.7, pp.857-61, 2007.

K. Kondo, Y. Ishii, H. Ochi, T. Matsumoto, H. Yoshikawa et al., Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology, vol.358, pp.266-72, 2007.

K. Kondo, H. Ochi, T. Matsumoto, H. Yoshikawa, and T. Kanda, Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes, J Med Virol, vol.80, issue.5, pp.841-847, 2008.

E. Draper, S. L. Bissett, R. Howell-jones, D. Edwards, G. Munslow et al., Neutralization of nonvaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine, vol.29, pp.8585-90, 2011.

K. Kwak, R. Jiang, J. W. Wang, S. Jagu, R. Kirnbauer et al., Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types, PLoS One, vol.9, issue.5, p.97232, 2009.

C. Eklund, E. R. Unger, D. Nardelli-haefliger, T. Zhou, and J. Dillner, International collaborative proficiency study of Human Papillomavirus type 16 serology, Vaccine, vol.30, issue.2, pp.294-303, 2012.

H. Kelly, H. Faust, A. Chikandiwa, J. Ngou, H. A. Weiss et al., Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection, J Infect Dis, vol.218, issue.6, pp.927-936, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01890118

L. Bruni, G. Albero, B. Serrano, M. Mena, D. Gó-mez et al., Human Papillomavirus and Related Diseases in France, 2018.

I. Heard, H. A. Cubie, D. Mesher, and P. Sasieni,

, Characteristics of HPV infection over time in European women who are HIV-1 positive, BJOG, vol.120, issue.1, pp.41-50, 2013.

I. Heard, I. Etienney, V. Potard, I. Poizot-martin, C. Moore et al., High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women, Clin Infect Dis, vol.60, issue.10, pp.1559-68, 2015.

I. Heard, L. Tondeur, L. Arowas, M. Falguières, M. C. Demazoin et al., Human papillomavirus types distribution in organised cervical cancer screening in France, PLoS One, vol.8, issue.11, p.79372, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01643641

R. K. Ogembo, P. N. Gona, A. J. Seymour, H. S. Park, P. A. Bain et al., Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis, PLoS One, vol.10, issue.4, 2015.

T. G. Ginindza, X. Dlamini, M. Almonte, R. Herrero, P. E. Jolly et al., Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland, PLoS One, vol.12, issue.1, p.170189, 2017.

H. A. Kelly, B. Sawadogo, A. Chikandiwa, M. Segondy, C. Gilham et al., Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of anti-retroviral therapy, AIDS, vol.31, issue.2, pp.273-285, 2017.

D. C. Beachler, G. Jenkins, M. Safaeian, A. R. Kreimer, and N. Wentzensen, Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis, J Infect Dis, vol.213, issue.9, pp.1444-54, 2016.

F. A. Castro, A. Dominguez, K. Puschel, V. Van-de-wyngard, P. J. Snijders et al., prevalence and persistence of high-risk human papillomavirus infection among women in, BMC Infect Dis, vol.14, p.24990706, 2014.

P. S. De-araujo-souza, A. V. Ramanakumar, J. M. Candeias, P. Thomann, A. Trevisan et al., Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study, BMC Infect Dis, vol.14, p.25730386, 2014.

S. S. Wang, M. Schiffman, T. S. Shields, R. Herrero, A. Hildesheim et al., Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica, Br J Cancer, vol.89, issue.7, pp.1248-54, 2003.

T. F. Schwarz, M. Kocken, T. Petä-jä, M. H. Einstein, M. Spaczynski et al., Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in

M. Safaeian, X. Castellsagué, A. Hildesheim, S. Wacholder, M. H. Schiffman et al., Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials, J Infect Dis, vol.218, issue.1, pp.84-94, 2018.

A. Hildesheim, R. Herrero, S. Wacholder, A. C. Rodriguez, D. Solomon et al., Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial, JAMA, vol.298, issue.7, pp.743-53, 2007.

J. Palmroth, P. Namujju, A. Simen-kapeu, V. Kataja, H. M. Surcel et al., Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes

, Scand J Infect Dis, vol.42, issue.5, pp.379-84, 2010.

C. M. Roteli-martins, P. Naud, D. Borba, P. Teixeira, J. C. et al., Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up, Hum Vaccin Immunother, vol.8, issue.3, pp.390-397, 2012.

S. E. Olsson, S. K. Kjaer, K. Sigurdsson, O. E. Iversen, M. Hernandez-avila et al., Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection, Hum Vaccin, vol.5, issue.10, pp.696-704, 2009.

X. Castellsagué, N. Muñoz, P. Pitisuttithum, D. Ferris, J. Monsonego et al., End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age, Br J Cancer, vol.105, issue.1, pp.28-37, 2011.

H. Faust, L. Toft, P. Sehr, M. Müller, J. Bonde et al., Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines, Vaccine, vol.34, issue.13, pp.1559-1565, 2016.

C. J. Lacey, HPV vaccination in HIV infection, Papillomavirus Res, vol.8, p.100174, 2019.

, Human papillomavirus vaccines. WHO position paper. Releve epidemiologique hebdomadaire / Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations, vol.84, pp.118-149, 2009.

, World health organization. Global action plan for the prevention and control of noncommunicable diseases, 2013.